Association of plasma β-amyloid with MRI markers of structural brain aging the 3-City Dijon study

[1]  P. Wolf,et al.  Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study , 2015, Alzheimer's & Dementia.

[2]  F. Petit,et al.  Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition , 2015, Neurobiology of Aging.

[3]  B. Small,et al.  Identifying cost-effective predictive rules of amyloid-β level by integrating neuropsychological tests and plasma-based markers. , 2014, Journal of Alzheimer's disease : JAD.

[4]  B. Mazoyer,et al.  Longitudinal Assessment of Global and Regional Rate of Grey Matter Atrophy in 1,172 Healthy Older Adults: Modulation by Sex and Age , 2014, PloS one.

[5]  Ming-Jang Chiu,et al.  Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. , 2014, ACS chemical neuroscience.

[6]  G. Tseng,et al.  Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression , 2014, Molecular Psychiatry.

[7]  Hwamee Oh,et al.  Association of gray matter atrophy with age, β-amyloid, and cognition in aging. , 2014, Cerebral cortex.

[8]  Michael W. Weiner,et al.  The future of blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[9]  S. Fowler,et al.  Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β , 2013, Brain : a journal of neurology.

[10]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[11]  Christos Davatzikos,et al.  Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI , 2013, PloS one.

[12]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[13]  C. Iadecola,et al.  Brain and Circulating Levels of A&bgr;1–40 Differentially Contribute to Vasomotor Dysfunction in the Mouse Brain , 2013, Stroke.

[14]  B. Zlokovic,et al.  Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[15]  Deborah Blacker,et al.  Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. , 2012, Archives of neurology.

[16]  Paul M. Thompson,et al.  Common variants at 12q14 and 12q24 are associated with hippocampal volume , 2012, Nature Genetics.

[17]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[18]  C. Jack,et al.  Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.

[19]  Alan E Hubbard,et al.  Longitudinal change of biomarkers in cognitive decline. , 2011, Archives of neurology.

[20]  C. Jack,et al.  Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI , 2011, Acta Neuropathologica.

[21]  R. Mayeux,et al.  Plasma Aβ and PET PIB binding are inversely related in mild cognitive impairment , 2011, Alzheimer's & Dementia.

[22]  Philip S. Insel,et al.  CSF biomarker and PIB-PET–derived beta-amyloid signature predicts metabolic, grey matter and cognitive changes in nondemented subjects , 2011, Alzheimer's & Dementia.

[23]  D. Holtzman,et al.  Apolipoprotein E in Alzheimer's disease and other neurological disorders , 2011, The Lancet Neurology.

[24]  Tamara B Harris,et al.  Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. , 2011, JAMA.

[25]  Carole Dufouil,et al.  Effects of ApoE-ɛ4 allele load and age on the rates of grey matter and hippocampal volumes loss in a longitudinal cohort of 1186 healthy elderly persons , 2010, NeuroImage.

[26]  Berislav V. Zlokovic,et al.  Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging , 2010, Neuron.

[27]  C. Jack,et al.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.

[28]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[29]  Amity E. Green,et al.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects , 2010, Neurobiology of Aging.

[30]  G. B. Frisoni,et al.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.

[31]  F. Jessen,et al.  Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing , 2010, Experimental Neurology.

[32]  C. Rowe,et al.  Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.

[33]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[34]  S Ourselin,et al.  β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.

[35]  Katharina Buerger,et al.  Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum , 2009, CNS neuroscience & therapeutics.

[36]  Mark A Mintun,et al.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.

[37]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[38]  L. Buée,et al.  Association of plasma amyloid β with risk of dementia , 2009, Neurology.

[39]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[40]  Carole Dufouil,et al.  Association of White-Matter Lesions with Brain Atrophy Markers: The Three-City Dijon MRI Study , 2009, Cerebrovascular Diseases.

[41]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[42]  G. Frisoni,et al.  In vivo mapping of amyloid toxicity in Alzheimer disease , 2009, Neurology.

[43]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[44]  T. Montine,et al.  Biomarkers for cognitive impairment and dementia in elderly people , 2008, The Lancet Neurology.

[45]  J. Becker,et al.  Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.

[46]  B. Hyman,et al.  Plasma Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men , 2008 .

[47]  R. Petersen,et al.  Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .

[48]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[49]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[50]  John D E Gabrieli,et al.  Implicit memory and Alzheimer's disease neuropathology. , 2005, Brain : a journal of neurology.

[51]  Fabrice Crivello,et al.  Age- and sex-related effects on the neuroanatomy of healthy elderly , 2005, NeuroImage.

[52]  M. Weiner,et al.  Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia , 2005, Annals of neurology.

[53]  Carole Dufouil,et al.  No ɛ4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects , 2005, NeuroImage.

[54]  Peter J. Lenting,et al.  LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.

[55]  W. Markesbery,et al.  Delayed recall, hippocampal volume and Alzheimer neuropathology , 2004, Neurology.

[56]  R. Holman,et al.  Vascular Factors and Risk of Dementia: Design of the Three-City Study and Baseline Characteristics of the Study Population , 2003, Neuroepidemiology.

[57]  Marko Wilke,et al.  Bright spots: correlations of gray matter volume with IQ in a normal pediatric population , 2003, NeuroImage.

[58]  Dinggang Shen,et al.  Very High-Resolution Morphometry Using Mass-Preserving Deformations and HAMMER Elastic Registration , 2003, NeuroImage.

[59]  A Hofman,et al.  Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes , 2002, Neurology.

[60]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[61]  Karl J. Friston,et al.  Cerebral Asymmetry and the Effects of Sex and Handedness on Brain Structure: A Voxel-Based Morphometric Analysis of 465 Normal Adult Human Brains , 2001, NeuroImage.

[62]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[63]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[64]  L. Vignolo,et al.  Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. , 1998, Archives of neurology.

[65]  D. Louis Collins,et al.  Design and construction of a realistic digital brain phantom , 1998, IEEE Transactions on Medical Imaging.

[66]  J. Mazziotta,et al.  Rapid Automated Algorithm for Aligning and Reslicing PET Images , 1992, Journal of computer assisted tomography.

[67]  J. Bamburg,et al.  COMPARATIVE PEPTIDE MAPPING AND ISOELECTRIC FOCUSING OF ISOLATED SUBUNITS FROM CHICK EMBRYO BRAIN TUBULIN , 1979, Journal of neurochemistry.

[68]  K. Blennow,et al.  Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. , 2012, Journal of Alzheimer's disease : JAD.

[69]  R. Mayeux,et al.  Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[70]  C. Rowe,et al.  Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. , 2010, Journal of Alzheimer's disease : JAD.

[71]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[72]  A. James,et al.  The incorporation and metabolism of amyloid-beta into chylomicron-like lipid emulsions. , 2003, Journal of Alzheimer's disease : JAD.

[73]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .